TFAP2C Affects PI3K/AKT/mTOR Pathway‐Mediated EMT for Glioblastoma Development Through Transcriptional Regulation
Cell Biology International · 2025-11 · 49 (11) · 1411-1424
DOI: 10.1002/cbin.70062 ↗At a glance
Journal article in Cell Biology International, 2025-11. Written by Shilin Li and 4 co-authors. Institution: Department of Neurosurgery, Hunan University of Medicine General Hospital, Huaihua, China. Major MEDLINE topics: Glioblastoma, Transcription Factor AP-2, Epithelial-Mesenchymal Transition, Phosphatidylinositol 3-Kinases. 48 references. Funded by: This study was supported by Hunan Provincial Natural Science Foundation of China (2023JJ50246)..
Abstract (original language)
Transcription factor AP‐2 gamma (TFAP2C) plays a pro‐cancer role in various malignancies. Yet, the action of TFAP2C in glioblastoma (GBM) is unknown. This study aimed to investigate the effects of TFAP2C in GBM and the potential mechanism. TFAP2C knockdown in GBM cell lines was employed to examine its impact on cell proliferation, migration, and invasion (PMI), as well as epithelial‐mesenchymal transition (EMT) development, and its association with the PI3K/AKT/mTOR (PAM) pathway by co‐overexpressing PI3K or SC79 treatment (AKT agonist). The binding of TFAP2C and the PI3K promoter was predicted and validated. Finally, the above effects and mechanisms were verified in in vivo animal experiments. TFAP2C expression was strikingly heightened in human GBM cell lines and showed a negative correlation with patient survival. TFAP2C silencing inhibited GBM cell PMI, N‐cadherin and Vimentin expression, and the PAM pathway, and activated E‐cadherin and ZO‐1 expression. Overexpression of PI3K or SC79 treatment reversed the above changes, suggesting that TFAP2C promotes GBM cell PMI and EMT via the PAM pathway. Mechanistically, TFAP2C binds to the promoter of PI3K and regulates PI3K transcription. Finally, the in vitro results were further validated in animal experiments. In conclusion, TFAP2C promotes PI3K transcription through direct binding to the promoter of PI3K and activates the PAM pathway to promote GBM proliferation and EMT, providing a potential therapeutic target for GBM.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurosurgery, Hunan University of Medicine General Hospital, Huaihua, China.
- Department of Neurosurgery, Shaoyang Central Hospital, Shaoyang, China.
ORCID profiles: Kaiyuan Jiang
Funding
- This study was supported by Hunan Provincial Natural Science Foundation of China (2023JJ50246).
Cite
APA
Li, S., Liu, K., Li, X., Zi, H., & Jiang, K. (2025). TFAP2C Affects PI3K/AKT/mTOR Pathway‐Mediated EMT for Glioblastoma Development Through Transcriptional Regulation. Cell Biology International. https://doi.org/10.1002/cbin.70062
Vancouver
Li S, Liu K, Li X, Zi H, Jiang K. TFAP2C Affects PI3K/AKT/mTOR Pathway‐Mediated EMT for Glioblastoma Development Through Transcriptional Regulation. Cell Biology International. 2025. doi:10.1002/cbin.70062
BibTeX
@article{Li2025,
author = {Li, Shilin and Liu, Kebo and Li, Xiaoyang and Zi, Hao and Jiang, Kaiyuan},
title = {TFAP2C Affects PI3K/AKT/mTOR Pathway‐Mediated EMT for Glioblastoma Development Through Transcriptional Regulation},
journal = {Cell Biology International},
year = {2025},
doi = {10.1002/cbin.70062}
}
EUVIMED